Table 1.
Demographic characteristics and blood biochemical parameters of included the patients with Huntington’s disease (HD) and the normal controls (NC).
| NC | HD | |||
|---|---|---|---|---|
| (n = 20) | preHD (n = 9) | sympHD (n = 24) | All (n = 53) | |
| Age (years) | 52.70 ± 8.95 | 32.00 ± 7.93 * | 50.00 ± 10.81 | 47.96 ± 12.14 |
| Male (%) | 10 (50.00) | 1 (11.11) ** | 16 (66.66) | 427(50.94) |
| BMI | 23.42 ± 2.57 | 20.24 ± 2.41 | 21.87 ± 2.54 | 22.16 ± 2.77 |
| Pre-prandial glucose (mg/dL) | 93.30 ± 10.74 | 87.80 ± 7.93 | 98.34 ± 16.59 | 93.38 ± 12.15 |
| UHDRS | ||||
| Total motor score | 0 | 39.21 ± 19.30 | ||
| Independence scale | 100 | 66.67 ± 25.93 | ||
| Functional capacity | 13 | 6.38 ± 4.16 | ||
| Disease burden | 272.56 ± 182.39 | 457.50 ± 124.61 | ||
| Medications | ||||
| Tetrabenazine (%) | 0 | 0 | 6 (25.00) | |
| Benzodiazepines (%) | 3 (15.00) | 0 | 14 (58.33) | |
| Antipsychotics (%) | 0 | 0 | 11 (45.83) | |
| Antidepressants (%) | 0 | 0 | 8 (33.33) | |
| Ubidecarenone (%) | 0 | 0 | 10 (41.67) | |
BMI’ body mass index; HD’ Huntington’s disease, preHD’ presympatomatic Huntington’s disease; sympHD’ symptomatic Huntington’s disease; UHDRS’ Unified Huntington’s Disease Rating Scale. *: Statistically significant in comparison with NC and sympHD, p < 0.05. Kruskal–Wallis test with Dunn’s correction. **: Statistically significant in comparison with NC and sympHD, p < 0.05. Fisher’s exact test.